Abstract
SMN functions via recognition of arginine symmetric-dimethylated proteins by its Tudor domain, and scarcity of SMN leads to Spinal Muscular Atrophy (SMA). Here we report a potent and selective antagonist targeting the Tudor domain of SMN. This compound could inhibit the interaction between SMN and R1810me2s-POLR2A mimicking the SMN depletion results, thus this SMN antagonist could be used as an efficient tool to better understand SMN’s biological functions and molecular etiology in SMA.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.